Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Diseases of the Thyroid

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 20 articles: HTML format

Single Articles

September 2025
1. SEHGAL K
   Personalized Thyroidology: Molecular Rewiring of Thyroid Nodule Management.
   Clin Cancer Res. 2025 Sep 26. doi: 10.1158/1078-0432.CCR-25-2474.
   PubMed     Abstract available
   
   
   June 2025
2. DING M, Wu G, Zhang S, Xie R, et al
   Clinical implications and application of molecular testing in the diagnosis and management of thyroid nodules in the Chinese population.
   Clin Cancer Res. 2025 Jun 27. doi: 10.1158/1078-0432.CCR-25-0270.
   PubMed     Abstract available
   
   
   
3. HARRISON C, Blake AK, Su Y, Tang L, et al
   Contribution of Germline Predisposition to Pediatric Thyroid Cancer.
   Clin Cancer Res. 2025 Jun 27. doi: 10.1158/1078-0432.CCR-25-0631.
   PubMed     Abstract available
   
   
   March 2025
4. LEE J, Shin Y, Kwak J, Park HL, et al
   Validation of Diagnostic Utility of Washout CYFRA 21-1 in Lymph Node Metastasis of Thyroid Cancer.
   Clin Cancer Res. 2025 Mar 12. doi: 10.1158/1078-0432.CCR-24-3562.
   PubMed     Abstract available
   
   
   November 2024
5. LI Q, Zhang W, Liao T, Gao Y, et al
   An AI-driven preoperative radiomic subtype for predicting the prognosis and treatment response of patients with papillary thyroid carcinoma.
   Clin Cancer Res. 2024 Nov 13. doi: 10.1158/1078-0432.CCR-24-2356.
   PubMed     Abstract available
   
   
   June 2024
6. FRENCH JD, Haugen BR, Worden FP, Bowles DW, et al
   Combination Targeted Therapy with Lenvatinib and Pembrolizumab in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers.
   Clin Cancer Res. 2024 Jun 26. doi: 10.1158/1078-0432.CCR-23-3417.
   PubMed     Abstract available
   
   
   May 2024
7. HEFT NEAL ME, Haring CT, Bellile E, Jaffe CC, et al
   Phase II Clinical Trial of Intravenous Levothyroxine to Mitigate Pharyngocutaneous Fistula in Euthyroid Patients Undergoing Salvage Laryngectomy.
   Clin Cancer Res. 2024 May 9. doi: 10.1158/1078-0432.CCR-24-0782.
   PubMed     Abstract available
   
   
   
8. PENG X, Zhao H, Ye L, Hou F, et al
   Biomarker identification and risk prediction model development for differentiated thyroid carcinoma lung metastasis based on primary lesion proteomics.
   Clin Cancer Res. 2024 May 9. doi: 10.1158/1078-0432.CCR-23-3806.
   PubMed     Abstract available
   
   
   April 2024
9. READ ML, Brookes K, Zha L, Manivannan S, et al
   Combined Vorinostat and Chloroquine Inhibit Sodium-Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo.
   Clin Cancer Res. 2024;30:1352-1366.
   PubMed     Abstract available
   
   
   January 2024
10. LECHNER MG, Brent GA
    A New Twist on a Classic: Enhancing Radioiodine Uptake in Advanced Thyroid Cancer.
    Clin Cancer Res. 2024 Jan 10. doi: 10.1158/1078-0432.CCR-23-3503.
    PubMed     Abstract available
    
    
    December 2023
11. KIM YH, Yoon SJ, Kim M, Kim HH, et al
    Integrative multi-omics analysis reveals different metabolic phenotypes based on molecular characteristics in thyroid cancer.
    Clin Cancer Res. 2023 Dec 13. doi: 10.1158/1078-0432.CCR-23-2025.
    PubMed     Abstract available
    
    
    November 2023
12. SHEN C, Shi X, Wen D, Zhang Y, et al
    Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System.
    Clin Cancer Res. 2023 Nov 6. doi: 10.1158/1078-0432.CCR-23-2142.
    PubMed     Abstract available
    
    
    October 2023
13. FU H, Huang J, Zhao T, Wang H, et al
    Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study.
    Clin Cancer Res. 2023 Oct 6. doi: 10.1158/1078-0432.CCR-23-1983.
    PubMed     Abstract available
    
    
    September 2023
14. DUKE ES, Bradford D, Marcovitz M, Amatya AK, et al
    FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.
    Clin Cancer Res. 2023;29:3573-3578.
    PubMed     Abstract available
    
    
    August 2023
15. CHI Y, Zheng X, Zhang Y, Shi F, et al
    Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase â…¡ Trial.
    Clin Cancer Res. 2023 Aug 18:CCR-22-3406. doi: 10.1158/1078-0432.CCR-22-3406.
    PubMed     Abstract available
    
    
    June 2023
16. HU H, Ng TSC, Kang M, Scott E, et al
    Thyroid cancers exhibit oncogene-enhanced macropinocytosis that is restrained by IGF1R and promotes albumin-drug-conjugate response.
    Clin Cancer Res. 2023 Jun 8:CCR-22-2976. doi: 10.1158/1078-0432.CCR-22-2976.
    PubMed     Abstract available
    
    
    
17. BIKAS A, Ahmadi S, Pappa T, Marqusee E, et al
    Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes.
    Clin Cancer Res. 2023 Jun 1:OF1-OF8. doi: 10.1158/1078-0432.CCR-23-0278.
    PubMed     Abstract available
    
    
    May 2023
18. BIKAS A, Ahmadi S, Pappa T, Marqusee E, et al
    Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes.
    Clin Cancer Res. 2023 May 16:CCR-23-0278. doi: 10.1158/1078-0432.CCR-23-0278.
    PubMed     Abstract available
    
    
    
19. LIN Y, Qin S, Yang H, Shi F, et al
    Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer.
    Clin Cancer Res. 2023 May 15:CCR-22-3613. doi: 10.1158/1078-0432.CCR-22-3613.
    PubMed     Abstract available
    
    
    April 2023
20. LEBOULLEUX S, Do Cao C, Zerdoud S, Attard M, et al
    A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer.
    Clin Cancer Res. 2023 Apr 19:CCR-23-0046. doi: 10.1158/1078-0432.CCR-23-0046.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diseases of the Thyroid is free of charge.